BioVentrix added some $18 million to the $21.8 million it raised earlier this year, according to a regulatory filing.
The San Ramon, Calif.-based company said it pulled down a total of $40 million in the round from 162 unnamed investors, after reporting the earlier raise in April. The first sale was logged in August 2017, according to the filing.
In February, BioVentrix said that it won renewed German reimbursement for its Revivent TC transcatheter ventricular enhancement system.